Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Pushes Back Profit Target in 5-Year Plan, Eyes Intensive Investment in Oncology
November 1, 2018
- Chugai Drops Herceptin Patent Suits against Daiichi Sankyo, Pfizer
November 1, 2018
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Biogen Japan COO Ajai Sulekh Named as New President
November 1, 2018
- Daiichi Sankyo to Discontinue Development of Intradermal Flu Vaccine
November 1, 2018
- Astellas Sales Up 1.1% Driven by Xtandi, OAB Drugs, despite Slump in Japan Business
November 1, 2018
- Sanofi, Daiichi Sankyo to Terminate Marketing Partnership for Hib Vaccine in Japan; Sanofi to Take Over Sales from Jan.
November 1, 2018
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Mitsubishi Tanabe Sales Slip 1.7% as Radicava Boon Fails to Counter Japan Drop
October 31, 2018
- Mitsubishi Tanabe Paints Murky Outlook for US Sales Target on Parkinson’s Development Delay
October 31, 2018
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
- Otsuka Pharmaceutical Factory to Jointly Develop Regenerative Medicine Products with Startup
October 31, 2018
- Shionogi’s Half-Year Profits Renew Records, but Crestor Generics Weigh on Topline
October 30, 2018
- Shionogi Chief Confident about 70% Market Share for Xofluza in Japan
October 30, 2018
- Europe OKs Xtandi for All CRPC Cases
October 30, 2018
- JCR Initiates Development of Temcell for Epidermolysis Bullosa
October 30, 2018
- Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
October 29, 2018
- Fujifilm Signs MOU on Clinical Development of Favipiravir in China with 3 Chinese Partners
October 29, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…